Literature DB >> 31077073

Retrospective fractional dose reduction in Tc-99m cardiac perfusion SPECT/CT patients: A human and model observer study.

P Hendrik Pretorius1, Albert Juan Ramon2, Michael A King3, Arda Konik3, Seth T Dahlberg3, Mathew W Parker3, Naomi F Botkin3, Karen L Johnson3, Yongyi Yang2, Miles N Wernick2.   

Abstract

BACKGROUND: In the ongoing efforts to reduce cardiac perfusion dose (injected radioactivity) for conventional SPECT/CT systems, we performed a human observer study to confirm our clinical model observer findings that iterative reconstruction employing OSEM (ordered-subset expectation-maximization) at 25% of the full dose (quarter-dose) has a similar performance for detection of hybrid cardiac perfusion defects as FBP at full dose.
METHODS: One hundred and sixty-six patients, who underwent routine rest-stress Tc-99m sestamibi cardiac perfusion SPECT/CT imaging and clinically read as normally perfused, were included in the study. Ground truth was established by the normal read and the insertion of hybrid defects. In addition to the reconstruction of the 25% of full-dose data using OSEM with attenuation (AC), scatter (SC), and spatial resolution correction (RC), FBP and OSEM (with AC, SC, and RC) both at full dose (100%) were done. Both human observer and clinical model observer confidence scores were obtained to generate receiver operating characteristics (ROC) curves in a task-based image quality assessment.
RESULTS: Average human observer AUC (area under the ROC curve) values of 0.725, 0.876, and 0.890 were obtained for FBP at full dose, OSEM at 25% of full dose, and OSEM at full dose, respectively. Both OSEM strategies were significantly better than FBP with P values of 0.003 and 0.01 respectively, while no significant difference was recorded between OSEM methods (P = 0.48). The clinical model observer results were 0.791, 0.822, and 0.879, respectively, for the same patient cases and processing strategies used in the human observer study.
CONCLUSIONS: Cardiac perfusion SPECT/CT using OSEM reconstruction at 25% of full dose has AUCs larger than FBP and closer to those of full-dose OSEM when read by human observers, potentially replacing the higher dose studies during clinical reading.

Entities:  

Keywords:  Cardiac perfusion; SPECT/CT; dose fractionation; human observers

Mesh:

Substances:

Year:  2019        PMID: 31077073      PMCID: PMC6842418          DOI: 10.1007/s12350-019-01743-7

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  29 in total

1.  Accelerated image reconstruction using ordered subsets of projection data.

Authors:  H M Hudson; R S Larkin
Journal:  IEEE Trans Med Imaging       Date:  1994       Impact factor: 10.048

2.  Contemporary Cardiac SPECT Imaging-Innovations and Best Practices: An Information Statement from the American Society of Nuclear Cardiology.

Authors:  Brian G Abbott; James A Case; Sharmila Dorbala; Andrew J Einstein; James R Galt; Robert Pagnanelli; Renée P Bullock-Palmer; Prem Soman; R Glenn Wells
Journal:  J Nucl Cardiol       Date:  2018-10       Impact factor: 5.952

Review 3.  Subjecting Radiologic Imaging to the Linear No-Threshold Hypothesis: A Non Sequitur of Non-Trivial Proportion.

Authors:  Jeffry A Siegel; Charles W Pennington; Bill Sacks
Journal:  J Nucl Med       Date:  2016-08-04       Impact factor: 10.057

4.  Some practical issues of experimental design and data analysis in radiological ROC studies.

Authors:  C E Metz
Journal:  Invest Radiol       Date:  1989-03       Impact factor: 6.016

5.  Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT.

Authors:  T Ichihara; K Ogawa; N Motomura; A Kubo; S Hashimoto
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

6.  Reduced administered activity, reduced acquisition time, and preserved image quality for the new CZT camera.

Authors:  Jenny Oddstig; Fredrik Hedeer; Jonas Jögi; Marcus Carlsson; Cecilia Hindorf; Henrik Engblom
Journal:  J Nucl Cardiol       Date:  2012-11-10       Impact factor: 5.952

7.  The radiation dose to overweighted patients undergoing myocardial perfusion SPECT can be significantly reduced: validation of a linear weight-adjusted activity administration protocol.

Authors:  Jenny Oddstig; Cecilia Hindorf; Fredrik Hedeer; Jonas Jögi; Håkan Arheden; Magnus J Hansson; Henrik Engblom
Journal:  J Nucl Cardiol       Date:  2016-08-09       Impact factor: 5.952

8.  Human-observer receiver-operating-characteristic evaluation of attenuation, scatter, and resolution compensation strategies for (99m)Tc myocardial perfusion imaging.

Authors:  Manoj V Narayanan; Michael A King; P Hendrik Pretorius; Seth T Dahlberg; Frederick Spencer; Ellen Simon; Eric Ewald; Edward Healy; Kirk MacNaught; Jeffrey A Leppo
Journal:  J Nucl Med       Date:  2003-11       Impact factor: 10.057

9.  Feasibility of myocardial perfusion imaging with half the radiation dose in obese patients using ordered-subset expectation maximization with resolution recovery software.

Authors:  Nili Zafrir; Tamir Bental; Alejandro Solodky; Avi Ben-Shlomo; Israel Mats; Yosef Hassid; Doron Belzer; Alexander Battler; Ariel Gutstein
Journal:  J Nucl Cardiol       Date:  2012-12-22       Impact factor: 5.952

10.  Development and validation of a patient-tailored dose regime in myocardial perfusion imaging using conventional SPECT.

Authors:  J D van Dijk; P L Jager; J P Ottervanger; J de Boer; A H J Oostdijk; E M Engbers; C H Slump; S Knollema; J A van Dalen
Journal:  J Nucl Cardiol       Date:  2015-09-09       Impact factor: 5.952

View more
  2 in total

1.  Deep learning, another important tool for improving acquisition efficiency in SPECT MPI Imaging.

Authors:  Ernest V Garcia
Journal:  J Nucl Cardiol       Date:  2020-05-17       Impact factor: 5.952

2.  Deep learning with noise-to-noise training for denoising in SPECT myocardial perfusion imaging.

Authors:  Junchi Liu; Yongyi Yang; Miles N Wernick; P Hendrik Pretorius; Michael A King
Journal:  Med Phys       Date:  2020-11-23       Impact factor: 4.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.